Dechra Pharmaceuticals plc (LON:DPH) insider Ian Page sold 54,910 shares of the stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of GBX 2,024 ($27.29), for a total transaction of £1,111,378.40 ($1,498,420.39).

Shares of Dechra Pharmaceuticals plc (LON DPH) opened at 1990.00 on Friday. The firm’s market capitalization is GBX 1.85 billion. Dechra Pharmaceuticals plc has a one year low of GBX 1,225.00 and a one year high of GBX 2,149.00. The stock has a 50 day moving average of GBX 1,904.89 and a 200-day moving average of GBX 1,783.03.

The company also recently announced a dividend, which will be paid on Friday, November 17th. Stockholders of record on Thursday, October 26th will be given a dividend of GBX 15.33 ($0.21) per share. This is a boost from Dechra Pharmaceuticals plc’s previous dividend of $6.11. This represents a dividend yield of 0.74%. The ex-dividend date is Thursday, October 26th.

WARNING: “Dechra Pharmaceuticals plc (DPH) Insider Sells £1,111,378.40 in Stock” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/22/dechra-pharmaceuticals-plc-dph-insider-sells-1111378-40-in-stock.html.

A number of research firms have issued reports on DPH. Stifel Nicolaus reiterated a “hold” rating and set a GBX 1,550 ($20.90) target price on shares of Dechra Pharmaceuticals plc in a report on Tuesday, July 11th. Jefferies Group LLC increased their target price on shares of Dechra Pharmaceuticals plc from GBX 1,565 ($21.10) to GBX 1,868 ($25.19) and gave the stock a “hold” rating in a report on Tuesday, September 5th. Numis Securities Ltd reiterated an “add” rating and set a GBX 1,890 ($25.48) target price on shares of Dechra Pharmaceuticals plc in a report on Thursday, July 6th. N+1 Singer reiterated a “buy” rating and set a GBX 1,666 ($22.46) target price on shares of Dechra Pharmaceuticals plc in a report on Thursday, July 6th. Finally, Investec reiterated a “buy” rating and set a GBX 1,840 ($24.81) target price on shares of Dechra Pharmaceuticals plc in a report on Thursday, July 6th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of GBX 1,784 ($24.05).

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.